Abstract
Aims
To describe the results in terms of local control, eye preservation and systemic evolution of iris melanomas treated by proton beam irradiation.
Methods
Retrospective review of the charts of patients with iris melanoma treated by proton beam therapy between April 1998 and September 2002. Ciliary body melanomas with iris involvement or tumours with extrascleral invasion were excluded. Treatment consisted of 60 Gy of proton beam irradiation delivered in four fractions to the tumour volume.
Results
A total of 21 patients were treated, median follow-up of 33 months (8–72 months). 15 patients presented a lesion with documented growth. The median clinical diameter was 5 mm (2–8 mm), the median ultrasound diameter 4.8 mm (2–7.7 mm) The patients were 6% T1, 57.1% T2, and 14.3% T3 all N0M0. The iridocorneal angle was invaded by the tumour in 71.4% of patients. At the end of follow-up, all patients were alive with no proven metastatic disease except one patient with suspicious liver lesions. None of the patients showed tumour progression or ocular relapse. The tumour response at 2 years was a flat lesion for 6.3% of cases, partial regression in 75% and stable in 18.8%. None of the patients required secondary enucleation. The main complication was cataract (45% within 24 months of treatment). Raised intraocular pressure was observed in 15% of patients but no neovascular glaucoma.
Conclusions
Proton beam therapy shows potential utility for selected cases of localised iris melanomas allowing excellent local tumour control and eye preservation. Further follow-up on larger series is needed to confirm these results.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Shields J, Shields C . Melanocytic tumors of the iris stroma. In: Shields J, Shields C (eds.). Intraocular Tumors A Text and Atlas. Saunders, 1992, pp. 69–77.
Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A . Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001; 108 (1): 172–178. Order.
Harbour JW, Augsburger JJ, Eagle Jr RC . Initial management and follow-up of melanocytic iris tumors. Ophthalmology 1995; 102 (12): 1987–1993.
Damato B . Uveal melanoma. In: Damato B (ed). Ocular Tumours. Oxford: Butterworth-Heinemann, 2000, pp. 57–93.
Marigo FA, Finger PT . Anterior segment tumors: current concepts and innovations. Surv Ophthalmol 2003; 48 (6): 569–593. Order.
Shields CL, Naseripour M, Shields JA, Freire J, Cater J . Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol 2003; 135 (5): 648–656.
Gupta M, Puri P, Rennie IG . Iris seeding following iridocyclectomy for localised iris melanoma. Eye 2001; 15 (Part 6): 808–809.
Spatola C, Privitera G, Raffaele L, Salamone V, Cuttone G, Cirrone P et al. Clinical application of proton beams in the treatment of uveal melanoma: the first therapies carried out in Italy and preliminary results (CATANA Project). Tumori 2003; 89 (5): 502–509.
Conway RM, Chua WC, Qureshi C, Billson FA, Harbour JW, Augsburger JJ et al. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 2001; 85 (7): 848–854.
Char DH, Kroll SM, Castro J . Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol 1998; 125 (1): 81–89.
Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119 (7): 969–982.
Egger E, Zografos L, Munkel G, Bohringer T, Bercher L, Chamot L . Results of proton radiotherapy for uveal melanomas. Front Radiat Ther Oncol 1997; 30: 111–122.
Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD . Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys 2001; 49 (4): 1053–1059.
Gragoudas ES, Seddon JM, Egan K, Glynn R, Munzenrider J, Austin-Seymour M et al. Long-term results of proton beam irradiated uveal melanomas. Ophthalmology 1987; 94 (4): 349–353.
Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW . Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement. Arch Ophthalmol 1999; 117 (2): 170–177.
Zografos L, Perret C, Gailloud C . Conservative treatment of uveal melanoma by accelerated proton beam. In: Bornfeld N, Gragoudas E, Höpping W, Lommatzsch P, Wessing A, Zografos L (eds). Tumors of the eye. Proceedings of the second international symposiumon diagnosis and treatment of intraocular tumors, Geneva, Switzerland, November 23–23 1987. Amsterdam/New York: Kugler publications, 1991, pp. 497–506.
Wilson MW, Hungerford JL . Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999; 106 (8): 1579–1587.
Zografos L . Mélanomes iriens. In: Zografos L (ed). Tumeurs Intraoculaires. Paris: Masson, 2002, pp. 291–302.
Gragoudas ES, Egan KM, Seddon JM, Walsh SM, Munzenrider JE . Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology 1992; 99 (5): 760–766.
Gragoudas ES, Seddon J, Goitein M, Verhey L, Munzenrider J, Urie M et al. Current results of proton beam irradiation of uveal melanomas. Ophthalmology 1985; 92 (2): 284–291.
Cardine S, Labetoulle M, Kirsch O, Di Nolfo M, Offret H, Frau E . Iris melanomas. A retrospective study of 11 patients treated by surgical excision. J Fr Ophtalmol 2003; 26 (1): 31–37.
Jensen OA . Malignant melanoma of the iris. A 25-year analysis of Danish cases. Eur J Ophthalmol 1993; 3 (4): 181–188.
Author information
Authors and Affiliations
Corresponding author
Additional information
None of the authors have any financial interest
The series has been presented as an oral presentation at the 40th Particle therapy Co Operative Group, Paris, June 2004
Rights and permissions
About this article
Cite this article
Lumbroso-Le Rouic, L., Delacroix, S., Dendale, R. et al. Proton beam therapy for iris melanomas. Eye 20, 1300–1305 (2006). https://doi.org/10.1038/sj.eye.6702102
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702102
Keywords
This article is cited by
-
Proton therapy of iris melanoma with 50 CGE
Strahlentherapie und Onkologie (2017)
-
Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases
Graefe's Archive for Clinical and Experimental Ophthalmology (2014)
-
Don’t it make my blue eyes brown: heterochromia and other abnormalities of the iris
Eye (2012)
-
Multifocal iris melanoma treated with total anterior segment palladium-103 plaque radiation therapy
Graefe's Archive for Clinical and Experimental Ophthalmology (2011)
